Search clinical trials for: bevacizumab erlotinib hydrochloride

Total 10081 results

Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

Pancreatic Cancer

Spain
PD Dr. med. Volker Heinemann
Roche Pharma AG

Unknown

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Yonggao Mou
The First Affiliated Hospital of Nanchang University

Recruiting

Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

Glioblastoma

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Hoffmann-La Roche

Completed

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Pancreatic Cancer

Italy
Hoffmann-La Roche

Terminated

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Pancreatic Cancer

Mexico
Hoffmann-La Roche

Completed

A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash (MATER)

Non-Squamous Non-Small Cell Lung Cancer

Sweden
National Cancer Center, Korea
Pfizer; Roche Pharma AG

Unknown

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

NSCLC | Lung Cancer

Korea, Republic of
LungenClinic Grosshansdorf

Unknown

Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (TIE)

Non-Small Cell Lung Cancer

Germany
Tony Reid, M.D., Ph.D.
Genentech, Inc.

Completed

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Hikma Pharmaceuticals LLC

Terminated

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Carcinoma, Non-Small-Cell Lung

Lebanon, Jordan
Hospices Civils de Lyon

Completed

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

France
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

Germany
Hoffmann-La Roche

Terminated

A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Australia
Chinese Lung Cancer Surgical Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Chinese PLA... and other collaborators

Unknown

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Non-small Cell Lung Cancer Stage IIIA

China
Henan Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Guangdong Provincial People's Hospital

Unknown

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (TREND)

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor

China
Indiana University School of Medicine
Genentech, Inc.

Completed

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Pancreatic Cancer

United States
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
Henan Cancer Hospital

Completed

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Soft Tissue Sarcomas

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
M.D. Anderson Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer

United States
Herbert J. Zeh, III MD, FACS
Genentech, Inc.

Terminated

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

Pancreatic Cancer

United States
Groupe Français de Pneumo-Cancérologie

Completed

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

France
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma | Recurrent Urethral Urothelial Carcinoma | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage 0a Bladder Cancer... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

EGFR-Mutant Lung Cancer

United States
University of Pittsburgh
OSI Pharmaceuticals

Completed

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Liver Cancer

United States
M.D. Anderson Cancer Center

Completed

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
University of Arkansas
OSI Pharmaceuticals

Terminated

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Metastatic Breast Cancer

United States
Ottawa Hospital Research Institute
Ozmosis Research Inc.

Completed

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Non-Small Cell Lung Cancer | Squamous Cell Carcinoma

Canada
Jinming Yu
Roche Pharma AG

Unknown

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (RECEL)

Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Fudan University

Unknown

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center
Genentech, Inc.

Withdrawn

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Lung Cancer

United States
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Pancreatic Cancer

Greece
Gyeongsang National University Hospital
Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Dong-A...

Completed

Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Korea, Republic of
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Hepatocellular Carcinoma | Cirrhosis

United States
AbbVie

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Belgium, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Taiwan
Jonsson Comprehensive Cancer Center

Completed

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Nathan Pennell, MD, PhD
National Cancer Institute (NCI)

Completed

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer

China
Fox Chase Cancer Center

Withdrawn

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States

3

Subscribe